Archives
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
Fmoc-Ile-Wang resin Thiol are reduced by two major
2024-09-05
Thiol are reduced by two major redox systems, glutathione/glutaredoxin (GRX) and thioredoxin (TRX), which have been extensively studied in plants [13], [14], [15]. Glutathione, a thiol-containing tripeptide, exists in a reduced (GSH) or an oxidized form (GSSG). It has a major role as a redox buffer.
-
The Irbesartan Diabetic Nephropathy Trial
2024-09-05
The Irbesartan Diabetic Nephropathy Trial enrolled patients with type 2 diabetes, proteinuria of at least 0.9 g/24 h, BP >135/85 mmHg and moderate kidney impairment (creatinine 88 to 265 µmol/L in women or 106 to 265 µmol/L in men). Patients were randomized to receive irbesartan (titrated from 75 to
-
Hyperactivity of the hypothalamus pituitary adrenal HPA axis
2024-09-05
Hyperactivity of the hypothalamus-pituitary-adrenal (HPA) axis, which is well described in MDD (Pariante and Lightman, 2008, Marques et al., 2009), is also observed in AD and results in increased glucocorticoid (GC, cortisol in primates) levels in blood and CSF (Davis et al., 1986, Martignoni et al.
-
Cy5.5 carboxylic acid (non-sulfonated) Recently different ki
2024-09-05
Recently, different kinds of Aβ aggregation inhibitors have been reported, including small molecules [8], peptides [9], and nanoparticles (NPs) [10]. The working mechanisms of the inhibitors are mostly to bind or adsorb Aβ molecules and to affect the conformational changes followed by blocking the a
-
While there is much in vivo work on prion like
2024-09-05
While there is much in vivo work on prion-like Aβ, it has not been shown that one can induce inclusions of Aβ in cultured cells as has been shown for tau and α-synuclein. One reason is practical; Aβ is a low molecular weight metabolite cleaved from within the larger amyloid precursor protein (APP) a
-
An unbiased evaluation of hepatic
2024-09-05
An unbiased evaluation of hepatic mRNA was performed to assess the impact of hepatocyte AMPK activation on the transcriptome. The expression of 913 genes were altered in control mice after chronic PF-06409577 treatment, 188 genes were affected by knocking out AMPK in hepatocytes, and expression of 2
-
Not all secondary metabolites or
2024-09-05
Not all secondary metabolites or natural products can be fully synthesized due to their very complex structures that are too difficult and expensive on industrial scale. Hence, there is an urgent need to search for alternative remedies as naturally occurring biologically active secondary metabolites
-
br Acknowledgements This work was
2024-09-05
Acknowledgements This work was supported by Programme Grants from the MRC and the Wellcome Trust (SGC-C and MF). CB was in receipt of a Marie Curie Intra-European Fellowship during part of this work. We thank past and present members of our group for numerous valuable discussions throughout these
-
The specific mechanisms underlying glutamine dependency are
2024-09-05
The specific mechanisms underlying glutamine dependency are still being explored, and current research indicates that the mechanisms likely vary between breast cancer subtypes. In HER2-positive breast cancer, increased levels of the transcriptional activator PGC-1α lead to expression of genes that m
-
br Development of lorlatinib from crizotinib to a
2024-09-05
Development of lorlatinib from crizotinib (1) to a clinical candidate (6) Xalkori (1, PF-02341066, crizotinib), was the first-in-class ALK inhibitor approved by the Unites States Food and Drug Administration (FDA) in 2011 as a first-line treatment for ALK+- NSCLC patients. This section describes
-
In conclusion we have shown that
2024-09-05
In conclusion, we have shown that mGlu7 receptors negatively regulate α1-adrenergic receptor signalling in heterologous expression systems, Pranlukast receptor tissue and living animals. This interaction might represent a protective mechanism aimed at restraining an excessive activation of noradren
-
br Materials and methods br
2024-09-05
Materials and methods Results The average body weights for each group of mice over the course of the study are shown in Fig. 2A. The average body weights of the mice in the saline control group and PACAP group increased slightly during the study. In contrast, starting at day 17, the body weigh
-
A review has recently been published to evaluate the potenti
2024-09-04
A review has recently been published to evaluate the potential effects of food, alcohol and fludarabine mg juices on the pharmacokinetics and pharmacodynamics of the drugs for BPH. The authors reviewed the PubMed database during the years 1991–2015. In addition, a digital version of Stockley on drug
-
Introduction Chronic inflammation is increasingly known as
2024-09-04
Introduction Chronic inflammation is increasingly known as one of the most critical etiological factors in gastrointestinal (GI) cancers (Lee et al., 2016; Wang and Cho, 2015). Overexpression of 5-lipoxygenase (5-LOX), 5-LOX-activating protein (FLAP), as well as other leukotriene (LT) biosynthetic
-
Subsequently Palvimaki et al corroborated Ni
2024-09-04
Subsequently, Palvimaki et al. (1999) corroborated Ni and Miledi's study by demonstrating that treatment with fluoxetine leads to 43% occupancy of the 5-HT2C receptors. Moreover, the affinity of fluoxetine for 5HT2C receptors (Ki 65 nM) is close to its affinity for 5-HT transporters (Ki 33 nM) (Ni a
15929 records 88/1062 page Previous Next First page 上5页 8687888990 下5页 Last page